Emerging data suggest this peptide, a dual stimulator targeting both GLP-1 and GIP , appears to provide a promising advancement for obesity management . Initial patient trials have indicated https://getretatrutideaustralia.com/blog/retatrutide-vs-tirzepatide-semaglutide